林骁表示，阿斯利康也持续助力中国创新成果惠及全球患者。"我们与中金资本成立了阿斯利康中金医 疗产业基金，注册地就在无锡，目前在管资金规模约5.5亿美元，已投资27家中国创新企业，其中有6家 落户无锡，并有10家被投企业与跨国药企达成17项全球授权合作。" 截至目前，阿斯利康在无锡已累计投资超10亿美元，建立了无锡生产供应基地、亚太区域包装中心、以 及中国物流中心等。近期，阿斯利康总投资达4.75亿美元的小分子药物新工厂在无锡正式开工，建成后 将主要生产阿斯利康在研管线中的心血管创新药。 （文章来源：新华财经） 同时，阿斯利康与北京大学长三角未来技术生命健康研究院、英矽智能及上海长三角医创生命健康产业 基金会等产学研机构联合发起的"长三角AI生物医药产业联盟"正式成立。该联盟旨在加速AI与生物医药 深度融合，实现临床、学术及商业端的协同，打造具有全国影响力的AI生物医药产业创新平台，促进 中国医药产业从"制药"向"智药"升级。 记者了解到，阿斯利康自1993年进入中国以来，专注治疗领域包括肿瘤、心血管、肾脏、代谢、呼吸、 消化、罕见病、疫苗抗体及自体免疫等，已将40多款创新药物带到中国。 "我们持续扩大在华研发 ...

Group 1 - The core viewpoint of the news highlights a significant rise in the stock prices of innovative drug companies, with notable increases in companies like Shuyou Shen and Hehua Co., as well as a general positive trend in the innovative drug ETF market [1][5] - The innovative drug sector in China is expected to see active License-out transactions in Q1 2025, contributing significantly to global hot targets, supported by policy backing and AI empowerment, which may lead to both profit and valuation increases [5][13] - AstraZeneca's new small molecule drug factory in Wuxi has officially commenced operations, focusing on cardiovascular innovative drugs, with production expected to start in Q4 2028, indicating a deepening supply chain layout in China [5][6] Group 2 - The 2024 annual performance briefing for the innovative drug industry on the Sci-Tech Innovation Board included 18 companies, discussing the impact of potential U.S. drug tariffs, with most companies indicating minimal effects due to their limited exposure to the U.S. market [6][7] - Companies like Junshi Biosciences and Nanwei Technology are planning to advance their innovative drug products into critical registration clinical trials by 2025, indicating a strong pipeline for future growth [7][14] - The innovative drug ETF market is diverse, with various indices tracking different segments, including CS Innovation Drug and Hong Kong Innovation Drug, highlighting the growing interest and investment in this sector [9][11] Group 3 - The innovative drug industry is anticipated to transition from capital-driven growth to profit-driven growth by 2025, presenting opportunities for both performance and valuation recovery [13][14] - Continuous support policies for innovative drugs are expected to enhance market scale, including the introduction of the first Class B medical insurance directory and further price formation mechanisms [14][15] - The overall supply-demand dynamics in the innovative drug sector are improving, with a clear advantage on the demand side and a more favorable competitive landscape on the supply side, reinforcing the positive outlook for investment opportunities [15]

5月8日，阿斯利康无锡小分子药物新工厂正式开工。新工厂总投资达4.75亿美元，占地约3万平方米， 将装备两套前沿的片剂连续制造工艺设备和七条可持续药品包装生产线，主要生产阿斯利康在研管线中 的心血管创新药，预计于2028年第四季度投产。这是继上月青岛吸入气雾剂生产供应基地一期建筑主体 竣工后，阿斯利康在华供应链布局的进一步深化。(第一财经) ...